patent for semaglutide Ozempic's problem: how Novo Nordisk lost control of a blockbuster drug. 💉 Demand GLP-1 weight-loss drugs has exploded, turning Ozempic into a $40bn+ revenue engine for Novo Nordisk. But, despite Obesity Drugs Set To Take

It offers full-on virtual health care for just about any ailment, so if, for example, you get a sinus infection while youre on GLP-1s, you can use your PlushCare membership to sign up for an appointment (which will cost $119 without insurance) and be treated from home

PG-R: Writing original draft, Writing review & editing, Writing original draft

A related version, Wegovy, was cleared specifically for obesity

In fact, over the past several years, the percentage of plan spending on GLP-1 medications has increased faster than other diabetic medications

Wegovy, a medication containing semaglutide, is a GLP-1 receptor agonist utilized for weight management in adults with obesity or overweight conditions